- Home
- ICHR vs PRTA Comparison
ICHR vs PRTA Comparison
Compare ICHR & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICHR
- PRTA
- Stock Information
- Founded
- ICHR 1999
- PRTA 2012
- Country
- ICHR United States
- PRTA Ireland
- Employees
- ICHR N/A
- PRTA N/A
- Industry
- ICHR Semiconductors
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- ICHR Technology
- PRTA Health Care
- Exchange
- ICHR Nasdaq
- PRTA Nasdaq
- Market Cap
- ICHR 581.2M
- PRTA 472.1M
- IPO Year
- ICHR 2016
- PRTA N/A
- Fundamental
- Price
- ICHR $16.48
- PRTA $8.06
- Analyst Decision
- ICHR Strong Buy
- PRTA Buy
- Analyst Count
- ICHR 6
- PRTA 10
- Target Price
- ICHR $29.80
- PRTA $12.29
- AVG Volume (30 Days)
- ICHR 781.6K
- PRTA 869.0K
- Earning Date
- ICHR 11-03-2025
- PRTA 11-11-2025
- Dividend Yield
- ICHR N/A
- PRTA N/A
- EPS Growth
- ICHR N/A
- PRTA N/A
- EPS
- ICHR N/A
- PRTA N/A
- Revenue
- ICHR $929,180,000.00
- PRTA $10,341,000.00
- Revenue This Year
- ICHR $14.64
- PRTA N/A
- Revenue Next Year
- ICHR $5.82
- PRTA $602.32
- P/E Ratio
- ICHR N/A
- PRTA N/A
- Revenue Growth
- ICHR 15.45
- PRTA N/A
- 52 Week Low
- ICHR $13.12
- PRTA $4.32
- 52 Week High
- ICHR $36.48
- PRTA $22.41
- Technical
- Relative Strength Index (RSI)
- ICHR 42.87
- PRTA 49.02
- Support Level
- ICHR $16.60
- PRTA $8.10
- Resistance Level
- ICHR $17.70
- PRTA $8.50
- Average True Range (ATR)
- ICHR 0.78
- PRTA 0.33
- MACD
- ICHR 0.10
- PRTA -0.10
- Stochastic Oscillator
- ICHR 39.73
- PRTA 3.45
About ICHR Ichor Holdings
Ichor Holdings Ltd is engaged in the design, engineering, and manufacturing of critical fluid delivery subsystems and components for semiconductor capital equipment. The product offerings include gas and chemical delivery subsystems, collectively known as fluid delivery subsystems, which are key elements of the process tools used in the manufacturing of semiconductor devices. The company also manufactures machined components, weldments, and proprietary products for use in fluid delivery systems. Geographically, the company operates in the United States, Singapore, Europe, and Others, of which a majority of the revenue is generated from Singapore.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.